
| Manufacturer | Bulk Vaccine Antigen | Oil-In-Water Bulk Adjuvant |
| Novartis | $150 million | $139 million |
| GlaxoSmithKline | $ 38 million | $144 million |
| Sanofi | $191 million | |
| CSL Biotherapies | $180 million | |
| MedImmune | $ 90 million | |
| Total | $649 million | $283 million |
HHS has contracted with these manufacturers that currently hold U.S. licenses for flu vaccine as part of the National Strategy for Pandemic Influenza. In May 2009, HHS issued new orders on these contracts to produce a bulk supply of vaccine antigen and adjuvant and to produce pilot (also called investigational) lots of a 2009 H1N1 vaccine. Most will be stored in bulk, and a small amount will be prepared as vaccine for use in clinical studies to evaluate vaccine safety and the dosage required for a protective effect. This research will include studies with adjuvant to determine its safety and the effect it would have on the immune system’s response.
If you would like to make a comment, please fill out the form below.